The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

i am a healthcare professional i am not a healthcare professional
Head-to-Head vs Sulfonylurea
Contact Us Patient Site Site Map

JANUMET® XR
(sitagliptin and metformin HCl
extended-release) tablets

JANUMET®
(sitagliptin/metformin HCI)
tablets

JANUVIA®
(sitagliptin)
tablets

JUVISYNC™
(sitagliptin and simvastatin)
tablets

Patient
Support Resources

Hypothetical Patient Profiles

JANUVIA: Similar A1C reductions with less hypoglyomeia and no weigth gain vs glipizide1

JUVISYNC ™ (sitagliptin and simvastatin) tablets hypothetical patient Jim

Actor Portrayal.

Joe, Age 57

  • 6'1", 240 lb
  • BMI: 32
  • Uncontrolled on metformin alone
  • Current A1C: 7.7%


For appropriate patients with type 2 diabetes, consider adding JANUVIA


 
JUVISYNC ™ (sitagliptin and simvastatin) tablets hypothetical patient Joyce

Actor Portrayal.

Joan, Age 45

  • 5’5”, 160 lb
  • BMI: 26.6
  • Concerned about managing her weight
  • Current A1C: 8.0%

For appropriate patients with type 2 diabetes, add the power of JANUVIA              

BMI = body mass index

 

Selected Important Risk Information
There have been postmarketing reports of serious hypersensitivity reactions in patients treated with JANUVIA, such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Onset of these reactions occurred within the first 3 months after initiation of treatment with JANUVIA, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue JANUVIA, assess for other potential causes for the event, and institute alternative treatment for diabetes.

Angioedema has also been reported with other dipeptidyl peptidase-4 (DPP-4) inhibitors. Use caution in a patient with a history of angioedema with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with JANUVIA.

View Additional Selected Important Risk Information

Important Information

JANUVIA® (sitagliptin) tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.

Before prescribing JANUVIA® (sitagliptin) tablets, please read the Prescribing Information. The Medication Guide also is available.

Reference: 1. Nauck MA, Meininger G, Sheng D, et al; for Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205.

This site is intended for health care professionals of the United States, its territories, and Puerto Rico.

Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of  Merck & Co., Inc. All rights reserved.

DIAB-1050515-0002 12/12

Close
12.
Del Prato S, Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res. 2004;36:775–781.
Close
13.
Ahrén B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 2003;3:365–372.
Close
47.
Nauck MA, Meininger G, Sheng D, et al; for Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194–205.